Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin-Reference-Cited by-同舟云学术

Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin

Published:2016-03-03 Issue:22 Volume:7 Page:32006-32014
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bosch-Barrera Joaquim¹²³,Sais Elia¹,Cañete Noemí²⁴,Marruecos Jordi²⁵,Cuyàs Elisabet²⁶,Izquierdo Angel¹²³,Porta Rut¹²³,Haro Manel²³⁷,Brunet Joan¹²³,Pedraza Salvador²³⁴,Menendez Javier A.²⁶

Affiliation:

1. Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain

2. Girona Biomedical Research Institute (IDIBGi), Girona, Spain

3. Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

4. Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain

5. Department of Radiotherapy, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain

6. ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain

7. Department of Pneumology, Doctor Josep Trueta University Hospital, Girona, Spain

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevention of Brain Metastases: A New Frontier;Cancers;2024-06-04

2. Silibinin is a suppressor of the metastasis-promoting transcription factor ID3;Phytomedicine;2024-06

3. Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes;Neuro-Oncology;2024-01-25

4. Targeting the Epigenetic Landscape for Cancer Therapy;Drugs from Nature: Targets, Assay Systems and Leads;2024

5. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25